Therapy Areas: Infectious Diseases
Moderna Partners with Takeda and the government of Japan to Supply Additional 50m Doses of Moderna's COVID-19 Vaccine and Variant Booster Vaccine Candidate in 2022
20 July 2021 - - The Ministry of Health, Labour and Welfare of Japan and Japanese pharmaceutical company Takeda Pharmaceutical Company Ltd. (TSX: 4502) (NYSE: TAK) have agreed to purchase and distribute an additional 50m doses of Moderna's COVID-19 vaccine and its updated variant booster vaccine candidate, if authorized, to begin delivery in 2022, US-based biotechnology company Moderna, Inc. (NASDAQ: MRNA) said.

This new supply agreement is in addition to the prior agreement for 50m doses in 2021 resulting in a total of 100m doses for Japan.

Moderna is responsible for the manufacture and supply of Moderna's vaccine candidate, and Takeda, with the support of the MHLW and Moderna, is responsible for all import, local regulatory, development and distribution activities in Japan for these additional 50m doses beginning in 2022.

In 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA, to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed.

Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna's capabilities have come together to allow the authorized use of one of the earliest and most-effective vaccines against the COVID-19 pandemic.

Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases.

Currently, 24 development programs are underway across these therapeutic areas, with 15 programs having entered the clinic. Moderna has been named a top biopharmaceutical employer by Science for the past six years.
Login
Username:

Password:


Related Headlines